Intensive Care Med. 2021 Jan;47(1):60-73. doi: 10.1007/s00134-020-06294-x. Epub 2020 Oct 29.
To describe acute respiratory distress syndrome (ARDS) severity, ventilation management, and the outcomes of ICU patients with laboratory-confirmed COVID-19 and to determine risk factors of 90-day mortality post-ICU admission.
COVID-ICU is a multi-center, prospective cohort study conducted in 138 hospitals in France, Belgium, and Switzerland. Demographic, clinical, respiratory support, adjunctive interventions, ICU length-of-stay, and survival data were collected.
From February 25 to May 4, 2020, 4643 patients (median [IQR] age 63 [54-71] years and SAPS II 37 [28-50]) were admitted in ICU, with day-90 post-ICU admission status available for 4244. On ICU admission, standard oxygen therapy, high-flow oxygen, and non-invasive ventilation were applied to 29%, 19%, and 6% patients, respectively. 2635 (63%) patients were intubated during the first 24 h whereas overall 3376 (80%) received invasive mechanical ventilation (MV) at one point during their ICU stay. Median (IQR) positive end-expiratory and plateau pressures were 12 (10-14) cmHO, and 24 (21-27) cmHO, respectively. The mechanical power transmitted by the MV to the lung was 26.5 (18.6-34.9) J/min. Paralyzing agents and prone position were applied to 88% and 70% of patients intubated at Day-1, respectively. Pulmonary embolism and ventilator-associated pneumonia were diagnosed in 207 (9%) and 1209 (58%) of these patients. On day 90, 1298/4244 (31%) patients had died. Among patients who received invasive or non-invasive ventilation on the day of ICU admission, day-90 mortality increased with the severity of ARDS at ICU admission (30%, 34%, and 50% for mild, moderate, and severe ARDS, respectively) and decreased from 42 to 25% over the study period. Early independent predictors of 90-day mortality were older age, immunosuppression, severe obesity, diabetes, higher renal and cardiovascular SOFA score components, lower PaO/FiO ratio and a shorter time between first symptoms and ICU admission.
Among more than 4000 critically ill patients with COVID-19 admitted to our ICUs, 90-day mortality was 31% and decreased from 42 to 25% over the study period. Mortality was higher in older, diabetic, obese and severe ARDS patients.
描述 COVID-19 重症患者的急性呼吸窘迫综合征(ARDS)严重程度、通气管理和 ICU 结局,并确定 ICU 出院后 90 天死亡率的危险因素。
COVID-ICU 是一项在法国、比利时和瑞士的 138 家医院进行的多中心前瞻性队列研究。收集了人口统计学、临床、呼吸支持、辅助干预、ICU 住院时间和生存数据。
2020 年 2 月 25 日至 5 月 4 日,4643 名(中位[IQR]年龄 63[54-71]岁,SAPS II 37[28-50])患者入住 ICU,4244 名患者可获得 ICU 出院后 90 天的状态。在 ICU 入院时,分别有 29%、19%和 6%的患者接受标准氧疗、高流量氧疗和无创通气。2635(63%)名患者在 24 小时内插管,而总体 3376(80%)名患者在 ICU 期间曾接受过有创机械通气(MV)。中位(IQR)呼气末正压和平台压分别为 12(10-14)cmH2O 和 24(21-27)cmH2O。MV 向肺部传递的机械功率为 26.5(18.6-34.9)J/min。在第 1 天插管的患者中,分别有 88%和 70%使用了麻痹剂和俯卧位。在这些患者中,207(9%)名患者诊断为肺栓塞,1209(58%)名患者诊断为呼吸机相关性肺炎。在 4244 名患者中,90 天时 1298 名(31%)患者死亡。在 ICU 入院当天接受有创或无创通气的患者中,ARDS 严重程度的 ICU 入院时死亡率分别为 30%、34%和 50%(轻度、中度和重度 ARDS),并在研究期间从 42%降至 25%。90 天死亡率的早期独立预测因素为年龄较大、免疫抑制、严重肥胖、糖尿病、较高的肾脏和心血管 SOFA 评分成分、较低的 PaO/FiO 比值和首次症状与 ICU 入院之间的时间较短。
在我们 ICU 收治的 4000 多名 COVID-19 重症患者中,90 天死亡率为 31%,并在研究期间从 42%降至 25%。年龄较大、糖尿病、肥胖和严重 ARDS 的患者死亡率更高。